Checkpoint Therapeutics (CKPT) Earning Somewhat Favorable News Coverage, Study Finds
Media headlines about Checkpoint Therapeutics (NASDAQ:CKPT) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Checkpoint Therapeutics earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.3670675893792 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
A number of research firms have recently issued reports on CKPT. Zacks Investment Research cut shares of Checkpoint Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. HC Wainwright began coverage on shares of Checkpoint Therapeutics in a research report on Friday, December 8th. They set a “buy” rating and a $11.00 price objective on the stock.
Checkpoint Therapeutics (NASDAQ CKPT) traded down $0.28 during mid-day trading on Friday, hitting $3.70. 117,600 shares of the stock were exchanged, compared to its average volume of 66,323. Checkpoint Therapeutics has a one year low of $3.20 and a one year high of $15.00.
Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.
Receive News & Stock Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related stocks with our FREE daily email newsletter.